Meeting to be held in New York on November 17 hosted by Piper Sandler.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVXL:
- Anavex announces U.S. FDA ODD to ANAVEX2-73 for treatment of FXS
- Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
- Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy